A nanoparticle-based vaccine candidate for H5N1 avian influenza achieved 100% protection in preclinical trials, offering hope ...

These were otherwise healthy school-age children who didn’t have to die.” We speak to the world-renowned pediatrician, ...

Biotech companies targeting rare diseases often lack the scale for in-house manufacturing or testing. US, NY, UNITED STATES, April 21, 2025 /E ...

DelveInsight's "HEMLIBRA Market Size, Forecast, and Market Insight Report" highlights the details around HEMLIBRA, a bispecific factor IXa- and factor X-directed antibody indicated for routine ...